Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, today announced that an ophthalmic solution made using its recombinant human albumin, has been approved for Phase I/II development by the FDA.
[More]
Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today the presentation of data for EBI-005, the first IL-1 (Interleukin-1) signaling inhibitor designed for topical ocular administration, at the Association for Research in Vision and Ophthalmology 2013 Annual Meeting in Seattle, Washington.
[More]
Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.
[More]
Clinical trial results point to a role for interleukin-1 targeted agents for the treatment of dry eye disease associated with meibomian gland dysfunction.
[More]
Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for sight threatening eye diseases, today announced that a phase 2b/3 clinical trial investigating emixustat hydrochloride in subjects with geographic atrophy associated with dry age-related macular degeneration has been initiated.
[More]
Dry eye disease (DED) is a common condition that causes discomfort, visual disturbance and potentially damaging ocular surface inflammation that greatly impacts a person's quality of life.
[More]
Natural lubricants play an important role in health, including a well-known effect to help prevent osteoarthritis in knee and ankle joints. However, much is still unknown about their role and function in other areas of the body.
[More]
AstraZeneca today announced top-line results of OSKIRA-1, a Phase 3 study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase inhibitor in development for rheumatoid arthritis.
[More]
Some of the last days of winter can be among the worst for your eyes. Winter may be slowly giving way to spring, but the remaining cold days of the season can cause plenty of trouble for the eyes—trouble that is largely avoidable, says a Vanderbilt Eye Institute ophthalmologist.
[More]
Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics, has published preclinical data in Proceedings of the National Academy of Sciences (PNAS) showing beneficial effects of EBI-005, the first rationally-designed topically administered IL-1 protein for the treatment of ocular diseases.
[More]
Clinicians with patients who have clinically significant dry eye should be on the alert for underlying Sjögren's syndrome, report researchers in the British Journal of Ophthalmology.
[More]
A simple test of eyelid sensitivity may help vision professionals in evaluating one of the most common eye-related symptoms: dry eyes. A new study linking increased eyelid sensitivity to decreased function of the eyelid margins is presented in the article - " Lid Margins: Sensitivity, Staining, Meibomian Gland Dysfunction, and Symptoms", appearing in the October issue of Optometry and Vision Science, official journal of the American Academy of Optometry.
[More]
InSite Vision Incorporated today announced that patient enrollment has been completed in the DOUBle Phase 3 clinical trial of AzaSite Plus (ISV-502) and DexaSite (ISV-305) for the treatment of blepharitis.
[More]
InSite Vision Incorporated today introduced DuraSite 2, its next-generation enhanced drug delivery system which provides a broad platform for developing superior ophthalmic therapeutics.
[More]
A new treatment available at the University of Michigan Kellogg Eye Center—prosthetic replacement of the ocular surface ecosystem or PROSE—provides relief to patients who suffer from severe dry eye, often the result of cancer or complex corneal disease.
[More]
InSite Vision Incorporated today reported financial results for the quarter ended June 30, 2012.
[More]
InSite Vision Incorporated today announced that patient enrollment has begun in the first Phase 3 clinical trial of BromSite (ISV-303) for the reduction of pain and inflammation after cataract surgery.
[More]
Acucela Inc., a clinical stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced the initiation of a Phase 3 clinical trial to evaluate rebamipide ophthalmic suspension in patients with dry eye syndrome.
[More]
BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement and a supply agreement with Jade Therapeutics, LLC, a developer of an ophthalmological therapeutic sustained-release drug delivery platform.
[More]
Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for EDI200, the company's novel, proprietary, recombinant protein.
[More]